Literature DB >> 20007540

Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells.

Simone Cuff1, Garry Dolton, R James Matthews, Awen Gallimore.   

Abstract

Although CD8+ T cells are usually considered antitumoral, several recent studies report that the cells can also promote tumor progression. Using the melanoma cell line B16 as a murine model of pulmonary metastasis, we examined whether the pro- versus antitumoral effects of CD8+ T cells relate to their Ag specificity. Results of the study indicate that although CD8+ T cells specific for tumor Ags promote tumor rejection, CD8+ T cells specific for unrelated Ags promote tumor progression. We found the effect to be partly attributable to CD8+ T cells dampening effective antitumor NK cell responses. Notably, activation of CD8+ T cell responses by an unrelated stimulus, in this case infection with influenza virus, increased the number of pulmonary tumor nodules. These data provide a rationale for previously unexplained data identifying contrasting roles for CD8+ T cells in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007540     DOI: 10.4049/jimmunol.0804089

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Emerging strategies for cancer immunoprevention.

Authors:  J C Roeser; S D Leach; F McAllister
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

2.  A role for B cells in facilitating defense against an NK cell-sensitive lung metastatic tumor is revealed by stress.

Authors:  Harlan P Jones; Beau Aldridge; Katherine Boss-Williams; Jay M Weiss
Journal:  J Neuroimmunol       Date:  2017-11-03       Impact factor: 3.478

3.  Genome-wide in vivo screen identifies novel host regulators of metastatic colonization.

Authors:  Louise van der Weyden; Mark J Arends; Andrew D Campbell; Tobias Bald; Hannah Wardle-Jones; Nicola Griggs; Martin Del Castillo Velasco-Herrera; Thomas Tüting; Owen J Sansom; Natasha A Karp; Simon Clare; Diane Gleeson; Edward Ryder; Antonella Galli; Elizabeth Tuck; Emma L Cambridge; Thierry Voet; Iain C Macaulay; Kim Wong; Sarah Spiegel; Anneliese O Speak; David J Adams
Journal:  Nature       Date:  2017-01-04       Impact factor: 49.962

Review 4.  Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.

Authors:  Rodolfo Daniel Cervantes-Villagrana; Damaris Albores-García; Alberto Rafael Cervantes-Villagrana; Sara Judit García-Acevez
Journal:  Signal Transduct Target Ther       Date:  2020-06-18

5.  L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy.

Authors:  H Angharad Watson; Ruban R P Durairaj; Julia Ohme; Markella Alatsatianos; Hanan Almutairi; Rebar N Mohammed; Miriam Vigar; Sophie G Reed; Stephen J Paisey; Christopher Marshall; Awen Gallimore; Ann Ager
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

6.  Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion.

Authors:  Ellyn Hughes; Sarah N Lauder; Kathryn Smart; Anja Bloom; Jake Scott; Emma Jones; Michelle Somerville; Molly Browne; Andrew Blainey; Andrew Godkin; Ann Ager; Awen Gallimore
Journal:  Cancer Immunol Immunother       Date:  2020-05-23       Impact factor: 6.968

7.  Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.

Authors:  H Angharad Watson; Garry Dolton; Julia Ohme; Kristin Ladell; Miriam Vigar; Sophie Wehenkel; James Hindley; Rebar N Mohammed; Kelly Miners; Rhys A Luckwell; David A Price; R James Matthews; Ann Ager
Journal:  Immunol Cell Biol       Date:  2016-07-19       Impact factor: 5.126

8.  Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response.

Authors:  Felipe V Pereira; Amanda Campelo L Melo; Jun Siong Low; Íris Arantes de Castro; Tárcio T Braga; Danilo C Almeida; Ana Gabriela U Batista de Lima; Meire I Hiyane; Matheus Correa-Costa; Vinicius Andrade-Oliveira; Clarice S T Origassa; Rosana M Pereira; Susan M Kaech; Elaine G Rodrigues; Niels Olsen S Câmara
Journal:  Oncotarget       Date:  2018-05-25

9.  Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.

Authors:  Genki Okumura; Akiko Iguchi-Manaka; Rikito Murata; Yumi Yamashita-Kanemaru; Akira Shibuya; Kazuko Shibuya
Journal:  J Exp Med       Date:  2020-03-02       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.